Apellis Pharmaceuticals Inc.

5 trials 1 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

4 Completed trials

9 Countries active

4 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 3 Phase II: 2

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

C3 glomerulopathy 2

Top IMPs

PEGCETACOPLAN 5 N. MENINGITIDIS GROUP C (STRAIN C11) POLYSACCHARIDE (DE-O-ACETYLATED) CONJUGATED TO TETANUS TOXOID, NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, NEISSERIA MENINGITIDIS GROUP Y POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN 1 PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 2, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A 1 RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE, OUTER MEMBRANE VESICLES (OMV) FROM NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 MEASURED AS AMOUNT OF TOTAL PROTEIN CONTAINING THE PORA P1.4 ADSORBED ON ALUMINIUM HYDROXIDE 1

All trials

5 total

A single arm study to evaluate the safety and biological activity of pegcetacoplan in patients 12- 17 years old with paroxysmal nocturnal he… Recruiting

2024-516350-22-00 Phase II 2 countries PEGCETACOPLAN
A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoprolifer… Ended

2023-504625-39-00 Phase III 8 countries N. MENINGITIDIS GROUP C (STRAIN C11) POLYSACCHARIDE (DE-O-ACETYLATED) CONJUGATED…
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patient… Ended

2024-514130-20-00 Phase III 4 countries PEGCETACOPLAN
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplan… Ended

2024-511544-36-00 Phase II 3 countries PEGCETACOPLAN
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects with Geographic Atrophy Secondary to … Ended

2024-512945-18-00 Phase III 7 countries PEGCETACOPLAN

Showing 1–5 of 5 trials

← All sponsors A–Z